Frontiers | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Drug Company Identifies Protein that Makes Mesothelioma More Susceptible to Treatment - Mesothelioma.net
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies | British Journal of Cancer
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase - ScienceDirect
Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism - ScienceDirect
ADI-PEG 20 plus Pem Cis for Mesothelioma Clinical Trial 2022 | Power
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies | British Journal of Cancer
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM | Cell Death & Disease
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
In-vivo antitumor activity of ADI-PEG20 alone, cisplatin alone, and in... | Download Scientific Diagram
ADI-PEG20 Improves PFS in ASS1-deficient Mesothelioma - Cancer Therapy Advisor
Study: Cancer Enzyme Slows Growth of Pleural Mesothelioma
Frontiers | A Glimpse in the Future of Malignant Mesothelioma Treatment
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
Cancers | Free Full-Text | Precision Therapy for Mesothelioma: Feasibility and New Opportunities
Mesothelioma: Current Best Practices and Promising Therapies - ppt download
ADI-PEG 20 treatment during PBMC stimulation and not under resting... | Download Scientific Diagram
Frontiers | Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Progress in the Management of Malignant Pleural Mesothelioma in 2017 - ScienceDirect
Accelerating innovations in systemic therapy for pleural mesothelioma | Nature Cancer
Novel therapies for malignant pleural mesothelioma - The Lancet Oncology
Arginine deprivation for ASS1-deficient mesothelioma
Benign Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma - ScienceDirect
A trial of a new drug called ADI-PEG 20 with chemotherapy for people with mesothelioma (ATOMIC-Meso) | Cancer Research UK
